Fundraising FoxAvoro Capital Advisors — 2014 Investments
4 investments dated 2014 · listed companies and verified rows first · show all
Adaptimmune Therapeutics is a biotechnology company, though the specific focus of their therapeutic work is not detailed on this investors and media page.
BiotechHealthtechMedical DevicesAbingdon, Oxfordshire, US
James Noble(Chief Executive Officer)Adrian Rawcliffe(Chief Executive Officer and Director)inGavin Wood(Chief Financial Officer)inWilliam Bertrand(Chief Operating Officer)inJohn Lunger(Chief Patient Supply Officer)inElliot Norry(Chief Medical Officer)in
Co-investorsEight Roads VenturesF-Prime CapitalForesite CapitalNew Enterprise Associates (NEA)Ridgeback Capital
Aerie Pharmaceuticals develops ophthalmic pharmaceutical products including Rocklatan and Rhopressa for glaucoma and ocular hypertension, and AR-15512 for dry eye disease.
BiotechHealthtechMedical DevicesBedminster, US
CASEY KOPCZYNSKI(Executive Officer)inVICENTE ANIDO(Executive Officer, Director)BRIAN LEVY(Executive Officer)RICHARD RUBINO(Executive Officer)THOMAS MITRO(Executive Officer)David Endicott(CEO of Alcon)in
Co-investorsAlta PartnersForesite CapitalOUP (Osage University Partners)Sofinnova Ventures
Ascendis Pharma is a biopharmaceutical company developing therapies for hormone-related disorders and rare diseases.
BiotechHealthtechMedical DevicesDenmark, DK
Jan Møller Mikkelsen(Founder, President and Chief Executive Officer)inGrethe Rasmussen(Executive Officer)inHarald Rau(Executive Officer)Martin Olin(Director)Lotte S?nderbjerg(Executive Officer)Martin Auster(Executive Officer)in
Co-investorsVivo CapitalAisling CapitalForesite CapitalRA CapitalSofinnova PartnersSofinnova Ventures
Global Blood Therapeutics was a South San Francisco biopharmaceutical company founded in 2011 focused on treatments for sickle cell disease.
South San Francisco, US
John Schembri(Executive Officer)inTed W. Love(Executive Officer, Director)in
BoardKevin Starr(Director)inCharles Homcy, M.D.(Director)
Co-investorsAisling CapitalRA CapitalRidgeback CapitalThird Rock VenturesWellington Management
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.